To: tsigprofit who wrote (11079 ) 3/20/2003 10:23:11 AM From: Findit Read Replies (1) | Respond to of 48461 TRIB up again. Now at 2.23. Zack's article: Gregory Spear Highlights the Following Stocks: Monolithic Systems, Central European Distributors, and Trinity Biotech 06:00 a.m. 03/20/2003 CHICAGO, Mar 20, 2003 (BUSINESS WIRE) -- Sometimes when you stir the pot, the cream rises to the top. Gregory Spear thinks he's found three such quality stocks and profiles them with his latest market and economic insights. Get his takes on Monolithic Systems (MOSY), Central European Distributors (CEDC), and Trinity Biotech (TRIB) . Click here for the full story exclusively on Zacks.com: Here are the highlights from the Featured Expert column: Earnings warning season has begun, so we can expect bombs in a variety of locations, literal and metaphoric. Until something bad happens to us on the military or domestic terror front, the media and the market will probably regard this war as a military Super Bowl of sorts. That's the tone of the reporting at the moment, anyway. A move by US forces into the DMZ between Kuwait and Iraq this morning boosted the index futures from red to green. New Consensus generally melted up on Tuesday as many 'second-tier' names played catch up with the market leaders. In the semiconductor space, that was the story for Monolithic Systems (MOSY) . The company makes specialized flash memory and is heavily shorted. For the fiscal year ended 12/02, revenues rose 24% to $27.8 million. Net income rose 77% to $12.4 million. Central European Distributors (CEDC) gained 8% on Tuesday on the best volume during this consolidation. Net revenue for the fourth quarter ended December 31, 2002 increased 98% to $113 million, net income increased 271% to $4.6 million, or $0.75 per fully diluted share. Net sales for the full year 2002 increased 64% to $294 million, and net income increased 229% to $8.3 million, or $1.49 per fully diluted share. Finally, take a look at Trinity Biotech (TRIB) . Trinity Biotech manufactures and markets over 300 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. In February TRIB reported revenues in Q4 rose 53% to almost $15 million, bringing $7.8 million to the bottom line, a 52% increase. The stock chart looks great and appears to be accelerating higher. Learn more about these companies and get additional market analysis from Gregory Spear, including his Armageddon Hedge portfolio, by clicking: About Zacks Featured Experts